OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in Combo with Zytiga

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today theinitiation of PACIFIC, an investigator-sponsored, randomized Phase 2 studyevaluating OGX-427 in men with metastatic castrate-resistant prostate cancer(CRPC) who are experiencing a rising PSA while receiving Zytiga (abirateroneacetate). The aim of the study is to determine if adding OGX-427 to Zytigatreatment can reverse or delay treatment resistance.Approximately 80 men who are being treated with Zytiga and have evidence of arising PSA, but no evidence of symptomatic or radiographic progression, willbe randomized to either continue treatment with Zytiga and prednisone alone,or have OGX-427 added to the Zytiga and prednisone treatment. Patients will bestratified based on whether they have received prior chemotherapy and willcontinue on study until symptomatic, radiographic or other documented diseaseprogression occurs. The primary objective will be to compare the two treatmentgroups for delaying further disease progression while on Zytiga by assessingthe progression-free survival (PFS) rate at 60 days after adding OGX-427.Secondary objectives include comparing the treatment arms for PSA responses,objective responses, time to progression, circulating tumor cells (CTCs) andother biomarkers.